Immix Biopharma Stock Jumps as Data Shows IMX-110 Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin
May 20, 2022 By MarketDepth
Immix Biopharma, Inc. (NASDAQ: IMMX) shares jumped more than 50% Friday after the Company revealed positive interim study data showing that after one cycle of treatment, ImmixBio’s lead candidate IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. In this study, IMX-110 was compared against approved drugs used to treat STS. Trabectedin was dosed according to Meco et. al., 2003 (trabectedin monotherapy treatment arm) and IMX-110 was administered at 2.0 mg/kg.
“We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies. We believe this is a preview of anti-tumor activity to be demonstrated in our 2 clinical trials to be kicked-off in 2022: IMX-110 monotherapy, and IMX-110 in combination with anti-PD-1 tislelizumab.”Ilya Rachman, MD PhD, CEO of ImmixBio
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children.